Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.14
NSPH's Cash to Debt is ranked higher than
66% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. NSPH: 2.14 )
NSPH' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 2.14

Equity to Asset 0.63
NSPH's Equity to Asset is ranked higher than
73% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. NSPH: 0.63 )
NSPH' s 10-Year Equity to Asset Range
Min: -5.28   Max: 0.91
Current: 0.63

-5.28
0.91
F-Score: 5
Z-Score: -15.08
M-Score: -2.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -263.74
NSPH's Operating margin (%) is ranked higher than
52% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. NSPH: -263.74 )
NSPH' s 10-Year Operating margin (%) Range
Min: -2890.06   Max: -263.75
Current: -263.74

-2890.06
-263.75
Net-margin (%) -273.41
NSPH's Net-margin (%) is ranked higher than
52% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.93 vs. NSPH: -273.41 )
NSPH' s 10-Year Net-margin (%) Range
Min: -4551.67   Max: -273.41
Current: -273.41

-4551.67
-273.41
ROE (%) -132.99
NSPH's ROE (%) is ranked lower than
51% of the 273 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. NSPH: -132.99 )
NSPH' s 10-Year ROE (%) Range
Min: -2681.37   Max: -40.32
Current: -132.99

-2681.37
-40.32
ROA (%) -84.64
NSPH's ROA (%) is ranked higher than
50% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. NSPH: -84.64 )
NSPH' s 10-Year ROA (%) Range
Min: -466.5   Max: -34.8
Current: -84.64

-466.5
-34.8
ROC (Joel Greenblatt) (%) -311.69
NSPH's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.09 vs. NSPH: -311.69 )
NSPH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -733.73   Max: -314.35
Current: -311.69

-733.73
-314.35
Revenue Growth (3Y)(%) 36.70
NSPH's Revenue Growth (3Y)(%) is ranked higher than
98% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. NSPH: 36.70 )
NSPH' s 10-Year Revenue Growth (3Y)(%) Range
Min: -72.9   Max: 50
Current: 36.7

-72.9
50
EBITDA Growth (3Y)(%) -20.90
NSPH's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. NSPH: -20.90 )
NSPH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 34.7
Current: -20.9

0
34.7
EPS Growth (3Y)(%) -20.70
NSPH's EPS Growth (3Y)(%) is ranked higher than
63% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. NSPH: -20.70 )
NSPH' s 10-Year EPS Growth (3Y)(%) Range
Min: -64.4   Max: 45.3
Current: -20.7

-64.4
45.3
» NSPH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NSPH Guru Trades in Q1 2014

John Keeley 26,000 sh (unchged)
» More
Q2 2014

NSPH Guru Trades in Q2 2014

Jim Simons 156,864 sh (New)
George Soros 58,000 sh (New)
John Keeley 26,000 sh (unchged)
» More
Q3 2014

NSPH Guru Trades in Q3 2014

John Keeley 26,000 sh (unchged)
George Soros Sold Out
Jim Simons 126,162 sh (-19.57%)
» More
Q4 2014

NSPH Guru Trades in Q4 2014

Jim Simons 284,462 sh (+125.47%)
John Keeley Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NSPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 19.84
NSPH's Forward P/E is ranked higher than
82% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NSPH: 19.84 )
N/A
P/B 0.90
NSPH's P/B is ranked higher than
96% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. NSPH: 0.90 )
NSPH' s 10-Year P/B Range
Min: 0.83   Max: 7.34
Current: 0.9

0.83
7.34
P/S 1.20
NSPH's P/S is ranked higher than
90% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. NSPH: 1.20 )
NSPH' s 10-Year P/S Range
Min: 1.16   Max: 185.74
Current: 1.2

1.16
185.74
EV-to-EBIT -0.32
NSPH's EV-to-EBIT is ranked lower than
58% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NSPH: -0.32 )
NSPH' s 10-Year EV-to-EBIT Range
Min: -6.4   Max: 0.1
Current: -0.32

-6.4
0.1
Current Ratio 2.23
NSPH's Current Ratio is ranked higher than
67% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. NSPH: 2.23 )
NSPH' s 10-Year Current Ratio Range
Min: 0.63   Max: 12.58
Current: 2.23

0.63
12.58
Quick Ratio 1.63
NSPH's Quick Ratio is ranked higher than
63% of the 290 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. NSPH: 1.63 )
NSPH' s 10-Year Quick Ratio Range
Min: 0.61   Max: 12.37
Current: 1.63

0.61
12.37
Days Inventory 415.45
NSPH's Days Inventory is ranked higher than
60% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 139.33 vs. NSPH: 415.45 )
NSPH' s 10-Year Days Inventory Range
Min: 181.04   Max: 5940.08
Current: 415.45

181.04
5940.08
Days Sales Outstanding 109.63
NSPH's Days Sales Outstanding is ranked higher than
63% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. NSPH: 109.63 )
NSPH' s 10-Year Days Sales Outstanding Range
Min: 14.43   Max: 124.07
Current: 109.63

14.43
124.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.41
NSPH's Price/Net Cash is ranked higher than
96% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NSPH: 4.41 )
NSPH' s 10-Year Price/Net Cash Range
Min: 1.68   Max: 8.71
Current: 4.41

1.68
8.71
Price/Net Current Asset Value 1.20
NSPH's Price/Net Current Asset Value is ranked higher than
99% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NSPH: 1.20 )
NSPH' s 10-Year Price/Net Current Asset Value Range
Min: 1.61   Max: 4.75
Current: 1.2

1.61
4.75
Price/Tangible Book 0.95
NSPH's Price/Tangible Book is ranked higher than
98% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. NSPH: 0.95 )
NSPH' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 4.32
Current: 0.95

1.45
4.32
Price/Median PS Value 0.04
NSPH's Price/Median PS Value is ranked higher than
100% of the 335 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. NSPH: 0.04 )
NSPH' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 2.73
Current: 0.04

0.08
2.73
Earnings Yield (Greenblatt) -310.00
NSPH's Earnings Yield (Greenblatt) is ranked lower than
72% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. NSPH: -310.00 )
NSPH' s 10-Year Earnings Yield (Greenblatt) Range
Min: -286.3   Max: 3849.2
Current: -310

-286.3
3849.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:3NSN.Germany,
Nanosphere, Inc., was incorporated in 1999 in Delaware. The Company develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables sensitive genomic and protein testing on a single platform. The Verigene System includes a bench-top molecular diagnostics workstation that is an advanced platform for genomic and protein testing. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. The Verigene System provides lower cost for laboratories already performing molecular diagnostic testing and enables smaller laboratories and hospitals without advanced diagnostic capabilities to perform genetic testing.
» More Articles for NSPH

Headlines

Articles On GuruFocus.com
comment on NSPH Mar 02 2013 
NANOSPHERE, INC. Reports Operating Results (10-Q) Aug 05 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 06 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) Nov 05 2009 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Apr 20 2015
Nanosphere Announces Reverse Split of Common Stock Apr 07 2015
NANOSPHERE INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Apr 07 2015
Nanosphere Announces Reverse Split of Common Stock Apr 07 2015
Scripps Study Illustrates Clinical and Economic Impact of Verigene BC-GP Rapid Blood Culture Test... Mar 25 2015
Verigene System Positioned to Provide Rapid Diagnosis of Outbreaks of CRE "Superbugs" Mar 12 2015
Verigene System Positioned to Provide Rapid Diagnosis of Outbreaks of CRE "Superbugs" Mar 12 2015
Nanosphere Announces Special Meeting of Stockholders and Filing of Definitive Proxy Statement With... Mar 03 2015
Nanosphere Announces Special Meeting of Stockholders and Filing of Definitive Proxy Statement With... Mar 03 2015
NANOSPHERE INC Financials Feb 18 2015
10-K for Nanosphere, Inc. Feb 13 2015
Nanosphere Announces Fourth Quarter and Full Year 2014 Results, 2015 Guidance and Next Generation... Feb 11 2015
Nanosphere Inc Earnings Call scheduled for 5:00 pm ET today Feb 11 2015
NANOSPHERE INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 11 2015
Nanosphere Announces Fourth Quarter and Full Year 2014 Results, 2015 Guidance and Next Generation... Feb 11 2015
Q4 2015 Nanosphere Inc Earnings Release - After Market Close Feb 11 2015
Nanosphere to Release Fourth Quarter & Fiscal Year 2014 Results and Host Investor Conference Call on... Feb 09 2015
Nanosphere Inc Announces Fourth Quarter and Full Year 2014 Preliminary Top Line Results Call... Jan 28 2015
NANOSPHERE INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in... Jan 28 2015
Nanosphere Announces Fourth Quarter and Full Year 2014 Preliminary Top Line Results, Director and... Jan 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK